Introduction {#S1}
============

Neurofibromatosis type 2 \[NF2; MIM \# 101000\] [@R01]^-^[@R04], previously known as bilateral acoustic neurofibromatosis \[BANF\] or central neurofibromatosis [@R05]^-^[@R08], is an autosomal dominant disorder caused by mutations in the NF2 gene \[MIM \# 607379\] [@R09] [@R10], encoding neurofibromin-2 or schwannomin \[SCH\], which is also called merlin \[moesin-ezrinradixin- like (ERM) protein\], on chromosome 22q12.2 [@R11]. Clinically, NF2 is characterised by the development of vestibular schwannomas (VSs), schwannomas of other cranial, spinal and cutaneous nerves, cranial and spinal meningiomas and/or other central nervous system (CNS) tumours including ependymomas and low grade astrocytomas [@R12]^-^[@R15]. A variety of ocular abnormalities are also common, such as early onset cataracts (usually asymptomatic), optic nerve sheath meningiomas, retinal and/or pigment epithelial hamartomas and epithelial retinal membranes [@R16]. Skin abnormalities include flat dermal (NF2-plaques) and spherical/ovoid subcutaneous nodular schwannomas [@R17]. Less than 1% of NF2 patients have \> 6 café-au-lait (CAL) spots [@R01]^-^[@R04] [@R17]. Clinically, affected individuals fall into two main groups[@R01] [@R18] [@R19]: (1) (Mild) Gardner type NF2 [@R06] [@R07], with bilateral VSs presenting in adulthood (mean age 22 to 27 years), often as the only feature[@R19]; (2) (Severe) Wishart type NF2 [@R05], with multiple (and rapidly progressive) CNS tumours other- than-VS which may present first, years before VSs [@R20]^-^[@R33]. The latter group also tends to have more marked skin and eye involvement [@R01]^-^[@R04] [@R20]^-^[@R33]. There is nonetheless substantial variation and patients may not fit neatly into one category. A third group, known as congenital NF2 [@R34], has been also recorded with bilateral VSs detected as early as the first days to months of life, which can be stable (and asymptomatic) for one to nearly two decades and thereafter suddenly progress: this form may be associated with (reversible) NF2 plaques in atypical locations (e.g., face, hands and feet) and other CNS tumours (e.g., meningiomas, ependymomas) [@R34].

Some individuals may also have NF2-related tumours localised to one part of the nervous system: e.g., a unilateral vestibular schwannoma with ipsilateral meningiomas or multiple schwannomas in one part of the peripheral nervous system (mosaic NF2): these phenotypes are caused by true somatic mutations of the NF2 gene [@R35]^-^[@R50].

Some other individuals develop multiple non-vestibular, non-intradermal cranial, spinal and peripheral \[histologically proven\] schwannomas and are usually referred as having schwannomatosis \[SWNTS\] [@R51]^-^[@R59]: two major clinical/molecular forms have been characterised so far, caused by mutation either in the SMARCB1 gene \[SWNTS1: MIM \# 162091\] located at 22q11.23 [@R60]^-^[@R62] or in the LTRZ1 gene \[SWNTS2: MIM \# 615670\] located at 22q11.21 [@R63]^-^[@R65].

Clinically overlapping features, between classical NF2 and alternate forms of NF2 \[i.e., mosaic NF2 and schwannomatosis\], are increasingly recorded [@R38] [@R40] [@R43]^-^[@R47] [@R50] [@R58] and only sometimes sorted out by means of molecular analysis [@R66] . Unilateral VSs (without NF2-related features) are relatively common in the general population \[7% of all primary CNS tumours\] as well as the occurrence of multiple meningiomas \[including familial multiple meningiomas\]. For all the above reasons and considerations, multiple sets of diagnostic criteria have been developed over the years for NF2 and its alternate/ related forms [@R44] [@R46] [@R55] [@R57]^-^[@R59] [@R67]^-^[@R72]. However, even individuals with bilateral VS especially late in life can have developed these by chance rather than having NF2 [@R50].

Clinical manifestations and natural history in the paediatric age {#S2}
=================================================================

Patterns of initial presentations {#s2a}
---------------------------------

The pattern(s) of presentation (and the natural history) of NF2 in childhood, are very protean and differ from adulthood in many respects [@R19]^-^[@R33]. In addition, children with NF2 whose onset is at or before puberty usually present differently from adolescents [@R28] [@R32] [@R34]. The most common initial symptoms in adult onset NF2 are usually attributed to eight cranial nerve dysfunction and include hearing loss, tinnitus, or balance dysfunction [@R01]^-^[@R04] [@R12]^-^[@R14] [@R73]. Conversely, in the pre-pubertal NF2 age group subtle skin tumours, small posterior capsular or cortical edge cataracts or neurological signs (see below) secondary to other-than-VSs cranial nerve(s) involvement and/or brainstem or spinal cord compression are more common and manifest long before dysfunction of cranial nerve VIII [@R19]^-^[@R34]. A reversal pattern is encountered in the congenital form of NF2 (see below) [@R34], whose first nervous system manifestation of the disease is the presence of small (i.e., less than 1 cm) bilateral VS, recorded (incidentally) as early as the first months or days (Zampino G., personal observation) of life.

Skin manifestations {#s2b}
-------------------

The initial clinical presentation of some NF2 children is when they manifest with few CAL spots (larger than in NF1, with more irregular margins and paler colour) ([Fig. 1](#F1){ref-type="fig"}), and/or peripheral nerve tumours ([Fig. 2](#F2){ref-type="fig"}) and are initially diagnosed as having either NF1 or sporadic benign neurofibromas or schwannomas, the revision of the diagnosis only occurring when the tumours are removed for histology showing a schwannoma not a neurofibroma or when other tumours become symptomatic or other NF2 features manifest [@R19] [@R23] [@R28] [@R32] [@R34]. Some of the cutaneous and nodular schwannomas are difficult to distinguish from neurofibromas from a clinical point of view. The only exception are the NF2-plaques which are schwannomas histologically and have a distinctive appearance as discrete, well-circumscribed, slightly raised pigmented cutaneous lesions ([Fig. 2](#F2){ref-type="fig"}) often containing excess hair and usually less than 2 cm in diameter[@R28] [@R34]. Another important aspect is that the NF2-plaques, in this young age group, are usually and typically (mostly) localised in the upper and lower limbs (and the hands, feet and the face in the congenital forms) ([Fig. 2 A-B](#F2){ref-type="fig"}) [@R23] [@R28] [@R34], differently from what is recorded in adult onset NF2 where the plaques are prevalently located in the trunk [@R01]^-^[@R04] [@R12]^-^[@R14].

![Close view up of the skin of a child with NF2 showing multiple café-au-lait spots of different size and shape (the largest are indicated by white arrows): note the paler brownish colour and the irregular size and margins.](0392-100X-36-345-g001){#F1}

###### 

Close view up of the skin of a toddler with \"congenital\" onset NF2 showing classical NF2 plaques (in atypical locations) over (A) the fingers (black arrows) and (B) the knee (white arrows).

![](0392-100X-36-345-g002a)

![](0392-100X-36-345-g002b)

Ophthalmologic manifestations {#s2c}
-----------------------------

Cataract is usually recorded in about 40% of NF2 children and is most commonly of the juvenile posterior sub-capsular or cortical types ([Fig. 3a](#F3){ref-type="fig"}). A further 25% of cases may have retinal hamartomas. Overall, cataract and/ or retinal changes are recorded in 40% to over 70% in the paediatric NF2 series so far reported [@R19] [@R23] [@R28] [@R30] [@R32]. Notably, Evans et al. [@R23] recorded lower overall figures (3.3%) for cataract in their NF2 children, but these had not undergone systematic ophthalmological examination. In all the large NF2 series, lens opacities have usually been asymptomatic but when they are large can affect visual acuity in approximately 20% of NF2 patients [@R19]^-^[@R33]. In childhood NF2 lens opacities can be detected by chance very early in life but often are thought to be sporadic and the children being discharged with follow-up [@R19] [@R24] [@R26]^-^[@R28]. When the same patients later develop hearing or neurological signs, whose association with cataracts should have alerted for NF2, diagnosis was suspected [@R28].

###### 

\(A\) Magnified view of the eye in an NF2 child showing subcapsular lens opacities (white arrow); and (B) Axial T2- weighted magnetic resonance image of the brain in a child with \"congenital\" NF2 showing a hypointense area (white arrows) in the intra-orbital region (\"intra-orbital meningioma\").

![](0392-100X-36-345-g003a)

![](0392-100X-36-345-g003b)

A significant number of NF2 children may have idiopathic strabismus or amblyopia before the development of other neurological symptoms that prompt the diagnosis of NF2 [@R23] [@R26]^-^[@R28]. Childhood onset strabismus and amblyopia have been frequently reported in adults with NF2 1 [@R01]^-^[@R04] [@R12]^-^[@R14]. Even though either sign has been regarded as non specific [@R20] we recorded both signs in children who later on in their NF2 course were shown at neuroimaging to have intraorbital or retro-orbital meningiomas ([Fig. 3b](#F3){ref-type="fig"}) or schwannomas of the third, fourth, sixth and seventh cranial nerves or tumours in the brainstem.

Otolaryngology manifestations {#s2d}
-----------------------------

Few NF2 children develop pure hearing or balance dysfunction as the first feature of their disease [@R19]^-^[@R33].

It must be noted that, in contrast to isolated unilateral VS, the NF2-associated VSs tend to cause symptoms at younger ages; in addition to that, NF2-associated VSs have larger size and a multilobulated macroscopic ([Figs. 4a-b](#F4){ref-type="fig"}) and microscopic appearance when compared with their sporadic counterpart [@R23] [@R28] and on MRI are clearly multifocal on both branches of the vestibular nerves almost invariably including the 7^th^ nerve branches and/or invading the internal auditory canal ([Fig. 4c](#F4){ref-type="fig"}) [@R71].

###### 

Axial T2-weighted (A) and T1-weighted contrast enhanced (gadolinium) (B) magnetic resonance images of the brain in an adolescent with Nf2 showing bilateral schwannomas (as hypointense lesions: white arrows) with intracanalar extension (outer white arrows); (C) Coronal T1-weighted contrast enhanced (gadolinium) magnetic resonance image of the brain in a child with NF2 showing bilateral schwannomas (as hyperintense lesions: white arrows) and multiple meningiomas (black arrows).

![](0392-100X-36-345-g004a)

![](0392-100X-36-345-g004b)

![](0392-100X-36-345-g004c)

Some otolaryngology features can be caused by (otherthan- eight) cranial nerve(s) involvement ([Fig. 5](#F5){ref-type="fig"}) and/or to brain meningiomas ([Fig. 6](#F6){ref-type="fig"}) [@R23]^-^[@R26] [@R28].

![Coronal T2-weighted magnetic resonance image of the brain showing a hyperintense aspect of the right hemi-tongue (seen in the left side of the Fig.: white arrows), which is atrophic because of a schwannoma of the 12th cranial nerve (note the normal aspect of the contralateral tongue delineated by the dashed white arrows).](0392-100X-36-345-g005){#F5}

###### 

Axial T1-weighted contrast enhanced (gadolinium) (A-B) magnetic resonance images of the brain showing multiple meningiomas as hyperintense lesions (\"meningiomatosis\").

![](0392-100X-36-345-g006a)

![](0392-100X-36-345-g006b)

Neurological phenotype {#s2e}
----------------------

Neurological manifestations are dictated by the presence, localisation and extension of the lesions in the cranial and/ or spinal regions and in the major cranial and/or peripheral nerve trunks: because of their initial, other-than-VSs, involvement most children with NF2 at onset may have isolated or multiple (other-than-eight nerve) cranial nerve deficits, neurological dysfunction related to intracranial, brainstem and/or spinal masses (most often meningiomas, schwannomas and ependymomas), including sensory and/ or motor deficits, seizures and/or visual field defects, and peripheral neuropathy (with muscle wasting) secondary to schwannomas.

There are neither intellectual impairment nor learning difficulties.

Central nervous system imaging, which in NF2 must include full brain and spinal MRI, usually assess the tumour burden and its progression over time. In almost all children with the Wishart type NF2 [@R24]^-^[@R26] [@R28] and in all children with congenital type NF2 [@R34] we also recorded high signal lesions in the cortical or periventricular regions resembling those of cortical dysplasia or cortical alterations of the polymicrogyria type. These hyperintensities (which do no enhance after gadolinium administration) have been so far attributed either to meningoangiomatosis or to hamartomatous tissue; the \"pure\" cortical dysplasia is often associated with other brain anomalies (e.g., colpocephaly). Interestingly, these cortical abnormalities do not behave as true masses or classical dysplasia being asymptomatic initially: however, after puberty we recorded generalised tonic-clonic seizures \[easily treatable with classical anticonvulsants (e.g., valproic acid)\] in most of these children with cortical abnormalities [@R28] [@R34].

The brainstem and/or the spine are usually involved by intrinsic tumours (e.g., ependymomas, astrocytomas) ([Fig. 7](#F7){ref-type="fig"}), intradural meningiomas ([Fig. 8a](#F8){ref-type="fig"}), and/or by peripheral schwannomas affecting the paravertebral ganglia and/or extending into the extra- or intradural spaces ([Fig. 8b](#F8){ref-type="fig"}).

###### 

Sagittal (A) and axial (B) T2-weighted magnetic resonance images of the spinal cord in a child with NF2 showing round hyperintense lesions of the cervical cord at the C1 level (intraspinal ependymoma).

![](0392-100X-36-345-g007a)
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###### 

Axial T1-weighted contrast enhanced (gadolinium) (A-B) magnetic resonance images of the spinal cord in an adolescent with NF2, showing (A) an intradural meningioma (white arrow) and (B) two schwannomas of the spinal nerves (white arrows).

![](0392-100X-36-345-g008a)

![](0392-100X-36-345-g008b)

Peripheral nervous system imaging reveals solitary or (more often) multiple schwannomas affecting, with variable extension, multiple nerves or multiple (major) nerve trunks and/or the paravertebral ganglia [@R20]^-^[@R33]. MRI is essential for initial diagnosis and differential diagnosis with NF1 and related forms, mosaic/segmental NF2 and schwannomatosis (see below).

Peripheral (axonal/demyelinating) neuropathy (confirmed by neurophysiology testing and without MRI evidence of underlying tumours) and monomelic atrophy (with wasting of a single limb) are frequently recorded (but often under-recognised) irrespective of age in children (and adults) with NF2 \[symmetric and/ or asymmetric distal sensorimotor neuropathy ranging from mild to severe degrees\] [@R20]^-^[@R33]: this neuropathy is thought to arise from neurofibromatous changes in peripheral nerves.

Congenital NF2 {#s2f}
--------------

This form is characterised by the occurrence of [@R20] [@R23] [@R27] [@R34]: (1) small (\< 1 cm), bilateral vestibular schwannomas (VSs) detected (as an incidental finding) at MRI by the first months of life ([Fig. 9a](#F9){ref-type="fig"}) \[or at birth: Zampino G., et al. at the Department of Paediatrics of the Catholic University of Rome, Italy, 2015; personal observation\] that are asymptomatic for 10 to 15 years, with usually sudden and rapid (\< 12 months) progression; (2) development of large numbers of skin NF2 plaques mainly in atypical locations (i.e., face, hands and knees) ([Fig. 2](#F2){ref-type="fig"}), which reverted to normal skin appearance at the time of VSs progression in the series so far reported [@R34]; (3) lens opacities ([Fig. 1](#F1){ref-type="fig"}) and NF2 retinal changes detected as early as the first months of life; (4) cortical malformations and/or diffuse (asymptomatic) high signal lesions at brain MRI in the periventricular regions; and (5) unaffected first-degree relatives who do not harbour NF2 gene abnormalities.

![Axial T1-weighted magnetic resonance image of the brain in a child with a congenital form of NF2 obtained at age 4 months showing bilateral vestibular schwannomas (case 1, ref. 34).](0392-100X-36-345-g009){#F9}

Pathophysiology: NF2 gene and merlin/schwannomin {#S3}
================================================

NF2 gene {#S3a}
--------

NF2 is caused by mutations in the NF2 gene at chromosome 22q12.1, which encodes for a protein called merlin or schwannomin, most similar to the exrin-readixin- moesin (ERM) proteins ([Fig. 10](#F10){ref-type="fig"}) [@R09]^-^[@R11]: these are membrane-cytoskeleton scaffolding proteins (i.e., linking actin filaments to cell membrane or membrane glycoproteins), which act as critical regulators of contact-dependent inhibition of proliferation and function at the interface between cell-to-cell adhesion, transmembrane signalling, and the actin cytoskeleton, thus contributing to maintain normal cytoskeletal organisation, to modulate cellular motility, attachment, remodelling and spreading and to regulate growth (tumour suppression function) [@R74].

![*Merlin-signalling pathway* - In more recent years, several lines of evidence have suggested that Merlin exists in multiple states, which vary from \"*fully open*\" to \"*fully closed*\" \[including \"*more closed*\" and \"*more open*\" states (see text for further explanation)\]. In its \"***more closed***\" frame **Merlin** is hyperphosphorylated (has many \"***P***\" groups) and connected to cytoskeletal actin (because of an increase in intra-molecular bounds - secondary to the increased \"P\" groups - which contribute to fold the protein structure) (**inactive Merlin**): thus, the *mitogen-signalling* pathway \[activated via the PAK and PKA pathways\], is active and increases the cellular proliferative phenomena; in its \"***more open***\" frame **Merlin** is dephosphorylated (has less \"***P***\" groups) and is disconnected from actin (**active Merlin**): thus, the *mitogen-signalling* pathway, is inactive and decreases cellular growth, survival and cellular motility. In *proliferating cells*: (a) interactions between the extracellular matrix and the GFR/RTK/integrin proteins (and their membrane receptors) trigger the Rac1/PAK pathway; and (b) interactions between the GPCR receptors and c-AMP trigger the PKA pathway, both activating in turn the structural changes of Merlin \[i.e., phosphorylation, increase in intra-cellular bounds and protein folding\], which switches to a \"*more closed*\" (inactive) state \[**A**: *inactivating pathway*\]. In *contact-inhibited cells*, different phosphatases (mediated by the adhesion junctions\' molecules and by HA bounds to CD44 receptors), via activation of the MYPT1 dephosphorylation and inhibition of the PAK/PKA pathway, dephosphorylate Merlin (→ switching to active form), which in turn leads to decreased cellular growth \[**B**: *activating pathway*\]. AJs = adhesion junction proteins; c-AMP = cyclic AMP; CD44 = antigen CD44; C-term = carboxy-terminal hydrophilic tail of the Merlin protein; coiledcoil = a structural motif (part) of the Merlin protein in which alpha-helices are coiled together like the strands of a rope; ERM = Ezrinradixin- moesin proteins; FERM = (F)-Four-point-one (4.1) protein-ERM domain of the Merlin protein (amino-terminal); GFR = growth factor receptor; GPCR = G-protein-coupled receptor; HA = hyaluronic acid; MYPT1 = myosin phosphatase target, subunit 1; P = phosphorylation groups; PAK = serine/threonine p21-activated kinase; PKA = protein kinase A enzyme; Rac1 = Rho family small GTP binding proteins; Rho = RAS homologue gene family; RTK = receptor tyrosine kinase; Ser-518 = Serine-518; Thr-230 = Threonine 230; + + + = stimulation; - - - = inhibition (from Ruggieri et al., 2015 [@R35] and Ruggieri et al., 2015 [@R36], adapted and modified).](0392-100X-36-345-g010){#F10}

Merlin structure and conformation {#S3b}
---------------------------------

### Merlin isoforms. {#S3ba}

The NF2 gene encodes two merlin isoforms [@R75]: (1) the longer, dominant isoform 1 (merlin-1 or merlin), a 595-residue protein, which presents an extended carboxy-terminal tail that is encoded by exon 17; and (2) the merlin isoform 2 (merlin-2), which contains an alternatively spliced exon 16 which ends in a stop codon, encoding 11 unique residues following amino acid 579 (as compared to Merlin-1) [@R76]. Merlin-2 lacks the carboxy- terminal residues required for intra-molecular binding between the amino-terminal FERM domain and the carboxy-terminal hydrophilic tail, possibly leading to a constitutively open conformation ([Fig. 10](#F10){ref-type="fig"}). In vitro and in vivo studies have demonstrated that merlin-2 inhibits cell proliferation and attenuates the downstream mitogenic signalling to the same extent of its isoform merlin-1 (thus, apparently irrespective of the open vs. closed state) [@R77].

### Merlin properties. {#S3bb}

The similarities of merlin to its familial group of ERM proteins are responsible for its cytoskeletal- binding properties: e.g., merlin links the cytoskeleton to the cell membrane either directly (through integral membrane proteins) or indirectly (through membraneassociated proteins) [@R78].

### Merlin domains. {#S3bc}

Merlin is divided into three structurally distinct regions: (1) an amino-terminal FERM (Fourpoint- one, ezrin, radixin, and moesin) domain; (2) a α-helical coiled-coil domain; and (3) a carboxy-terminal hydrophilic tail. The FERM domain shares 65% sequence identity with canonical ERMs, but, differently from the other ERM proteins, merlin lacks the actin-binding site in the C-terminal domain, which is highly conserved in the other ERMs protein providing these proteins with their function at the cortical cytoskeleton [@R79]. In merlin, the binding site of actin is located in the glutathione S-transferase N-terminal domain.

### \"Closed\" (active) vs. \"open\" inactive forms. {#S3bd}

Merlin switches from a closed state to an open state by phosphorylation at serine 518 ([Fig. 10](#F10){ref-type="fig"}) [@R80]. In the past decades, the evidence that Merlin-2 -which lacks the carboxy-terminal domain, thus lacking the possibility to reach a \"closed\" state - failed to exert tumour suppression activity and/or contact inhibition, led researchers to state that \"active\" merlin functioned in a closed conformation caused by the dephosphorylation at Serine-518, while the open form \[i.e., the solely form thought to reached by merlin-2\] was \"inactive\" and phosphorylated.

### \"More closed\" (inactive) vs. \"more open\" (active) forms. {#S3be}

In more recent years, the above (simplified) interpretation was questioned and several lines of evidence now suggest that merlin exists in multiple states, which vary from \"fully open\" to \"fully closed\". In addition to that, it was demonstrated [@R79] [@R81] that merlin-2 is able to suppress growth in mammalian cell lines, suggesting that the interdomain binding is dispensable for Merlin\'s adhesion signalling: the phosphorylated merlin \[merlin-2\] displays higher interdomain binding and therefore it is able to inhibit cell growth (even) in its open state. Furthermore, it has been observed that a stably closed merlin mutant does not suppress cell growth, whereas merlin-2 and the S-518 phospho- deficient mutant, which are defective in interdomain binding and therefore more open, can suppress cellular growth in the same way as it does the wild-type merlin. It is now accepted that the \"more open\" forms ([Fig. 10B](#F10){ref-type="fig"}) of merlin are more active as anti-oncogenic proteins, while the \"more closed\" forms ([Fig. 10A](#F10){ref-type="fig"}) lacks this function.

### FERM domain. {#S3bf}

Recent genetic evidence has suggested that a crucial role in Merlin\'s anti-tumour efficacy is played by the FERM domain, and in particular by the \"Blue-box motif\" within the subdomain F2, correspondent to the residues 177-183 in human merlin. In this respect, it is now well known that patients with truncating mutations show a more severe clinical picture, with a higher tumour burden. However, it must be said also that missense mutations involving residues 177-183 in the F2 domain can lead to more severe forms of NF2. Substitution of F2 domain with that of ERM protein Ezrin abolishes Merlin\'s anti-oncogenic activity, while substitutions of F1 or F3 domains does not affect cell proliferation [@R81] [@R82]. In contrast, mutations involving the coiled-coil region or the carboxy-terminal tail have rarely been observed in NF2 patients, thus demonstrating the crucial role of FERM domain in the pathogenesis of the disease [@R83]. It is presumable, that the α-helical domain and the C-terminus function in maintaining merlin in its inactive conformation during the normal biological cellular growth and could contribute to contact inhibition.

Post-translational regulation of Merlin {#S3c}
---------------------------------------

Merlin\'s function is mediated by different signalling pathways within the cell, which have been extensively characterised [@R84].

### Inactivating pathways. {#S3ca}

In proliferating cells, integrinmediated anchorage to the cell matrix and stimulation of receptor tyrosine kinases (RTKs) activate Rac \[Rac1/ p21-kinase\], in turn activating PAK and leading to phosphorylation of merlin at serine 518 ([Fig. 10B](#F10){ref-type="fig"}). Serine 518 phosphorylation increases the interdomain binding between Merlin\'s carboxy-terminus and FERM domain, maintaining merlin in a \"more closed\", inactive form: the inactivation is probably due to (a) masking of protein-interacting domains on FERM domain, which are necessary for downstream signalling or (b) occlusion of a presumable nuclear localization signal [@R85]. Merlin is inactivated mostly via the PAK/Rac pathway, which is initiated by RTK and Integrin receptors in the cell wall. The activation of PAK leads to the phosphorylation of Merlin in position 518 and the latter may be necessary for subsequent phosphorylation of other sites. Moreover, also protein kinase A enzymes can independently phosphorylate Merlin at serines 518 and 10 [@R86]: this could be particularly relevant in Schwann cells, which are sensitive to the cyclic AMPPKA signalling axis [@R87]. Protein kinase B, also named AKT, can induces phosphorylation at threonine 230 and serine 315, causing decreased interdomain binding, and the interaction with Phosphoinositide and PIKE-L [@R88]. Loss of PTEN function (related to an increased oncogenic risk) which results in increased PI3K-AKT activity can induce further merlin inactivation [@R77].

### Activating pathways. {#S3cb}

In contact-inhibited cells, dephosphorylated merlin accumulates ([Fig. 10B](#F10){ref-type="fig"}) as a result of intercellular adhesions, which lead to PAK inhibition [@R82] [@R84]. Different phosphatases may contribute in dephosphorylating merlin, regulating its activity, but the key role is played by cadherins and CD44 receptors, which activate merlin through its dephosphorylation by myosin phosphatase targeting subunit 1 (MYPT1) [@R89]. It has been showed that the protein kinase CPI-17 (c-potentiated phosphatase inhibitor 17 kDa weighed) inhibits MYPT1 and causes a reduced activation of merlin [@R90]. By contrast, cadherins cause loss of function of PAK protein, thus inhibiting the inactivation of Merlin.

Merlin downstream {#S3d}
-----------------

Effects mediated by Merlin in the membrane organisation of proteins include cell-to-cell adhesion, cytoskeletal architecture, interaction with cytosolic proteins and regulation of diverse downstream pathways, including nuclear and hippo pathway regulation.

Merlin-2, via the GTPase Rho/RhoKinase signalling network, promotes phosphorylation of neurofilaments that are neuron-specific intermediate filaments essential for axon structure and caliber [@R82].

Merlin-1 interacts with membrane associated proteins where it regulates the formation of membrane domain, with a function of contact inhibition, by interacting with several proteins localised in the plasma membrane, including other ERMs, the intracellular domain of CD44, α-catenin and angiomotin.

The interactions with α-catenin have been demonstrated in keratinocytes and skin epithelium: Merlin promotes the binding of β-catenin and Par3, needed for the maturation of adherence junctions, and with 14-3-3 protein, which sequesters phosphorylated YAP, suppressing YAP-mediated transcription. β-catenin also interacts with APC tumour suppressor, enhancing its activity [@R91]. The interaction with angiomotin regulates contact inhibition and tumour suppression through Patj, Pals1 and Mupp1 proteins by suppressing the Rac-PAK signalling. It is important to underline that both inactive and active forms of merlin interact with angiomotin, independently from growth suppressive stimuli [@R92]. Other interactions of merlin occur with cholesterol-dependent membrane domains as a result of phosphoinositide binding, or directly with cytoplasm proteins to control cytoskeletal dynamics, vesicular transport and microtubule stabilisation, which could function in promoting the transport of anti-mitogenic biomolecules or regulating the availability of growth factors in the cytoplasm [@R93]^-^[@R96].

In the nucleus, dephosphorylated Merlin inhibits the prooncogenic CRL4 ^DCAF1^ E3 ubiquitin ligase, even if Merlin lacks a canonical nuclear localisation sequence. It is presumable that Merlin interacts with the nucleus through a motif in the C-terminus promoting nuclear export by the CRM1-exportin pathway, or by FERM domain residues necessary for nuclear translocation [@R85].

The reduction of functions of CRL4is mediated by interactions of merlin with DCAF1 (DDB1 and Cul4-associated factor 1), a substrate recognition component of the CRL4 ^DCAF1^ complex, essential for epigenetic modifications that regulate DNA methylation and therefore gene transcription, in particular during embryogenesis and tumourigenesis [@R97]. Merlin\'s FERM domain binds one of the carboxy-terminal acidic tail of DCAF1, directly competing with CRL4 or causing structural changes, inhibiting its binding with CRL4 [@R85].

A further role of Merlin is in the Hippo pathway, which is a potent regulator of organ size in the whole animal kingdom. Disruption of this pathway causes organ overgrowth and tumourigenesis, through an overexpression of YAP and TAZ transcriptional coactivator, which lead to increased transcription of genes that drive proliferation, evasion of apoptosis and stemness [@R98] [@R99]. It has recently been shown that merlin can interact with Kibra to activate the Hippo kinase cascade, maybe through interactions and modulation of angiomotin in the tight junctions. Interestingly, angiomotin directly binds YAP and TAZ and retains them at the cortex.[@R100] Moreover, Merlin\'s inhibition of CRL4 ^DCAF1^ ligase causes a reduced inhibition of the Lats kinases, restrict YAP signalling [@R101].

The interplay of pathways {#S3e}
-------------------------

In summary, Merlin regulates proliferation acting via some cascades, which include Hippo/Mst and Warts/Lats proteins which in turn regulate the Yorkie/Yap complex on one side, and on the (RTK) Ras GAP/Raf proteins \[which regulate the MEK/ERK pathway\] and the PI3K/AKT proteins \[which regulate the mTOR pathway\] ([Figs. 10](#F10){ref-type="fig"}, [11](#F11){ref-type="fig"}) [@R74] [@R81] [@R84].

![Diagram showing the PIK3/AKT/MAPK signalling pathway (see text for explanation): AKT, AK (Akr mouse) strain transforming; BRAF, B-raf (rapidly accelerated fibrosarcoma); CRAF, C-raf (rapidly accelerated fibrosarcoma); CREB, cAMP response element-binding protein; 4EBP1, Eukaryotic translation initiation factor 4E-binding protein 1; ERK1, extracellular signal regulated kinase 1; ERK2, extracellular signal regulated kinase 2; GSK3, glycogen synthase kinase 3; HRAS, Harvey rat sarcoma viral (Vras) oncogene homolog; HRAS-GTP, Harvey rat sarcoma viral (V-ras) oncogene homolog glucose triphosphate; KRAS, Kirsten rat sarcoma viral (V-ras) oncogene homolog; KRAS-GTP, Kirsten rat sarcoma viral (V-ras) oncogene homolog glucose triphosphate; GF, growth factor; MAP2K1, mitogen activated protein 2 kinase 1; MAP2K2, mitogen activated protein 2 kinase 2; MDM2, mouse double minute 2 homolog; MEK1, MAPK-extracellular kinase 1; MEK2, MAPK-extracellular kinase 2; mTORC1, mammalian target of rapamycin complex-1; mTORC2, mammalian target of rapamycin complex-2; NFkb, nuclear factor kappa-light-chain-enhancer of activated B cells; NRAS, Neuroblastoma rat sarcoma viral (V-ras) oncogene homolog; NRAS-GTP, Neuroblastoma rat sarcoma viral (V-ras) oncogene homolog glucose triphosphate; p70S6K, protein 70 serine/threonine 6 kinase; p120-GAP, p120-GTPase activating protein; PDK1, Phosphoinositide dependent kinase 1; PIK3, phosphatidylinositol-3-kinase; PIK3CA, phosphatidylinositol- 3-kinase catalytic a subunit; PIK3R, phosphatidylinositol-3-kinase regulatory subunit; PIP2, phosphatidylinositol bi-phosphate; PIP3, phosphatidylinositol tri-phosphate; PP1C, protein phosphatase 1 catalytic subunit C; PTEN, phosphatase and tensin homolog; RAF, rapidly accelerated fibrosarcoma protein; Raptor, regulatory associated protein of mTOR; RAS-GTP, rat sarcoma viral (V-ras) oncogene homolog glucose triphosphate; RASA1, rat sarcoma viral (V-ras) oncogene homolog GTPase activating protein 1; Rictor, rapamycin insensitive companion of mTOR; RTK, tyrosine kinase receptor; SHOC1, suppressor of C. elegans homolog 1 protein; SHOC2, suppressor of C. elegans homolog 2 protein; SOS1, son of Sevenless 1 homolog; SPRED, Sprouty-related EVH1 domain-containing protein 1 (from Ruggieri et al., 2015 [@R36], adapted and modified).](0392-100X-36-345-g011){#F11}

Despite the common action on Ras/MEK/ERK and PI3K/ AKT/mTOR pathways, schwannomin does not interfere with learning and memory formation as it does neurofibromin (i.e., the affected protein in NF1) and the NF2 neurological phenotype seems, apparently, solely secondary to tumour formation and progression.

For the four-hit, three-steps model of tumourigenesis explaining the schwannomatosis phenotypes see below (under schwannomatosis) ([Fig. 12](#F12){ref-type="fig"}).

![The four hits-three steps model of tumourigenesis in schwannomatosis \[in the Fig. the SMARCB1 gene is represented, but the model is alike for the LZTR1 gene\]: (1) during the first step the constitutive SMARCB1 gene is inactivated (1^st^ hit); (2) in addition to the constitutional SMARCB1 mutation, a second step consists in the loss of chromosome 22q, or a segment of it, involving the two loci \[i.e., the wild-type SMARCB1 gene and the constitutional NF2 gene\] (2^nd^ and 3^rd^ hits); followed (3) by a somatic mutation of the remaining wild-type NF2 allele that constitutes the third step (4^th^ hit) giving rise to the local growth of the schwannoma (from Ruggieri et al., 2015 [@R36], adapted and modified).](0392-100X-36-345-g012){#F12}

Genotype-phenotype correlations {#S3f}
-------------------------------

Germline mutations occur throughout the first 15 exons but not in exons 16 and 17 of NF2 [@R49]. The predominant mutations are nonsense mutations at CpG islands but all forms of NF2 mutation occur including large multiexon and whole gene deletions. There is a relatively strong genotype phenotype correlation both with type and position of NF2 germline mutation [@R102]^-^[@R106].

Individuals with truncating mutations (nonsense/ frameshift) have earlier onset of symptoms, more meningiomas and spinal tumours and die younger. Truncating mutations in exon 1 and 14/15 cause milder disease. Splice site mutations are milder than truncating mutations and there is also a positional effect with early mutations being more severe. Large deletions/duplications are intermediate with missense mutations being associated with the mildest form[@R104] [@R106] [@R107].

Alternate/related forms of Neurofibromatosis 2 {#S4}
==============================================

Mosaic NF2 {#S4a}
----------

Some individuals may have a unilateral eighth-nerve schwannoma associated to ipsilateral meningiomas \[i.e., unilateral NF2 involvement of the CNS\] or multiple schwannomas localised to one part of the peripheral nervous system [@R35]^-^[@R50] (the latter going into the differential diagnosis with schwannomatosis: see below) [@R66]. As somatic mosaicism for the NF2 gene is the causative phenomenon they are also referred to as having mosaic NF2 [@R44].

Schwannomatosis {#S4b}
---------------

Schwannomatosis \[SWNTS\] is characterised by the development of multiple non-vestibular, non-intradermal cranial, spinal and peripheral schwannomas \[histologically proven\] [@R51]^-^[@R59]. Other NF2 features such as cataracts and ependymoma are absent, but meningiomas may occur with SMARCB1 mutations [@R108], even though these are not a prominent feature: SMARCB1 mutations are not a common cause of multiple meningiomas [@R109].

Two major clinical/molecular forms have been characterised so far [@R59]^-^[@R66]: (1) SWNTS1 \[MIM \# 162091\] [@R60]^-^[@R62] caused by constitutional (germ-line) inactivating mutations of the SMARCB1 gene \[SWI/SBF-related matrix-associated actin- dependent regulator of chromatin, subfamily B, member 1; MIM \# 601607\] located 6 Mb centromeric to the NF2 gene at 22q11.23, which encodes a SWI/SNF ATPdependent nuclear chromatin remodelling protein, which is part of a complex that: (a) relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively; (b) also binds to and enhances the DNA joining activity of HIV-1 integrase \[SWI/ SNF is a tumour suppressor implicated also in the genesis of malignant rhabdoid tumours\]. The SWNTS1 phenotype includes families with multiple schwannomas and multiple extra-axial/extra-medullary meningiomas (and also a unilateral vestibular schwannoma) [@R58]; and (2) SWNTS2 \[MIM \# 615670\] [@R63]^-^[@R65] caused by constitutional/germline inactivating mutations of the LZTR1 gene \[Leucine zipper-like transcriptional regulator 1; MIM \# 600574\], centromeric to the SMARCB1 gene at 22q11.21, which encodes a member of the BTB-kelch superfamily: it localises exclusively to the Golgi network where it may help stabilize the Golgi complex. The SWNTS2 phenotype is characterised by a later onset of disease (i.e., 20-60 years) and schwannomas affecting various body regions including extremities, spinal cord, chest wall and subcutaneous regions. To complicate matters, vestibular schwannomas do occur at a low frequency in individuals with LZTR1 mutations [@R65].

Mosaic NF2 and schwannomatosis {#S4c}
------------------------------

As stated above, schwannomatosis is partially explained by mutations in the SMARCB1 gene. Approximately 10- 15% of patients with schwannomatosis have a family history, while the remaining 85-90% have sporadic disease. About 40-50% of familial schwannomatosis, and less than 10% of sporadic patients, have an identifiable SMARCB1 mutation [@R60]^-^[@R62]. The other gene, LZTR1, has been recently reported to be mutated in \~80% of schwannomatosis patients negative for SMARCB1 mutation with evidence of a four hit mechanism [@R63]. However, further research has shown that a substantial portion of schwannomatosis remains unexplained by LZTR1 [@R64]^-^[@R65]. Schwannomas from SMARCB1 positive patients follow a four-hit, three-step model of tumourigenesis ([Fig. 12](#F12){ref-type="fig"}) in which both alleles of SMARCB1 and NF2 genes are inactivated in the tumour [@R60]^-^[@R66]. In addition to the constitutive SMARCB1 mutation, a second step consists in the loss of chromosome 22q, or a segment of it, involving the two loci, followed by a somatic mutation of the remaining wild-type NF2 allele that constitutes the third step and the four hit. The four-hit, three-step model is also present in schwannomas from LZTR1 patients, involving LZTR1 and NF2 genes. There is a phenotypic overlap among patients that are mosaic NF2 and patients with sporadic schwannomatosis, consisting of the presence of multiple non-vestibular nerve schwannomas. The sensitivity of blood genetic analysis is challenged in these situations and the histopathological features of schwannomas in either condition (i.e., NF2, schwannomatosis and mosaic NF2) are very similar. Recently [@R66], an adult patient with only multiple schwannomas in a single body segment (i.e., her leg) - thus, entirely fulfilling the diagnostic criteria for schwannomatosis - was demonstrated to harbour a double hit inactivation of the NF2 gene in two different schwannomas of the same body segment, demonstrating to be a true mosaic NF2 patient.

Diagnosis {#S5}
=========

Clinical criteria for the diagnosis of NF2 were first formulated at the National Institutes of Health (NIH) Consensus Conference on NF1 and NF2 in 1987 [@R67] and revised in 1990 [@R68]. These criteria emphasised the presence of bilateral VSs in a high percentage of NF2 patients ([Table I](#T1){ref-type="table"}). Alternatively, patients could qualify for a diagnosis of NF2 with a family history of NF2 and either unilateral VS or any two other tumours typically associated with NF2 ([Table I](#T1){ref-type="table"}). Under NIH criteria, however, patients without bilateral VSs or a family history of NF2 cannot qualify for a diagnosis of NF2. This was (and still is) particularly relevant for childhood NF2 whose initial presentation, and part of its natural history, progress without eight-nerve dysfunction and often lack affected members in the family tree.

###### 

Previous sets of diagnostic criteria for NF2.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NIH Criteria\                                                                                                                                                                   NIH Criteria\                                                                                                                                                                   Manchester Criteria\                                                                                                                                                            NNFF Criteria\
  \[1987\] [@R67]                                                                                                                                                                 \[1991\] [@R68]                                                                                                                                                                 \[1992\] [@R69]                                                                                                                                                                 \[1997\] [@R70]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Patients who meet either condition A or B have NF2*                                                                                                                            *Patients who meet either condition A or B have NF2*                                                                                                                            *Patients who meet either condition A, condition B, condition C, or condition D have NF2*                                                                                       *Patients who meet either condition A or B have NF2*

  A. Bilateral vestibular schwannoma                                                                                                                                              A. Bilateral vestibular schwannoma                                                                                                                                              A. Bilateral vestibular schwannoma                                                                                                                                              A. Bilateral vestibular schwannoma

  B. 1^st^ degree family relative with NF2 and either unilateral VS or any two of: neurofibroma, meningioma, glioma, schwannoma, or juvenile posterior subcapsular lens opacity   B. 1^st^ degree family relative with NF2 and either unilateral VS or any one of: neurofibroma, meningioma, glioma, schwannoma, or juvenile posterior subcapsular lens opacity   B. 1^st^ degree family relative with NF2 and either unilateral VS or any two of: neurofibroma, meningioma, glioma, schwannoma, or juvenile posterior subcapsular lens opacity   B. 1^st^ degree family relative with NF2 and either unilateral VS at \< 30 years of age or any two of: meningioma, schwannoma, glioma, juvenile lens opacity (posterior subcortical cataract or cortical cataract)

                                                                                                                                                                                                                                                                                                                                                                  C. Unilateral VS and any two of: neurofibroma, meningioma, glioma, schwannoma, or juvenile posterior subcapsular lens opacity                                                   

                                                                                                                                                                                                                                                                                                                                                                  D. Multiple meningiomas (≥ 2) and unilateral VS or any two of: neurofibroma, glioma, schwannoma, cataract                                                                       

  **Presumptive or probable NF2**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  *Patients who meet either condition C or D have probable NF2*

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  C. Unilateral VS \< 30 years of age and at least one of: meningioma, schwannoma, glioma, juvenile lens opacity

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  D. Multiple meningiomas and either unilateral VS \< 30 years of age or at least one of: schwannoma, glioma, juvenile lens opacity
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Revised criteria were proposed by the Manchester group in 1992 [@R69] and by the National Neurofibromatosis Foundation (NNFF) in 1997 ([Table I](#T1){ref-type="table"}) [@R70]. The goal of these revisions was to improve the sensitivity for patients with features associated with NF2 but who did not reach formal NIH criteria. None of these criteria, however, can distinguish perfectly unaffected adults and children from those with NF2 and each has its strengths and weaknesses. Unfortunately, mutational analysis cannot replace clinical criteria for diagnosis of NF2 since a causative mutation cannot be identified still in a high percentage of affected NF2 children. The diagnostic work-up is further complicated by the occurrence of alternate forms within the spectrum of NF2: i.e., mosaic NF2, schwannomatosis and multiple meningiomas, even though either form is rare in the paediatric age.

Baser et al. [@R71] [@R72] attempted to encompass all the above problems by empirically developing and testing an improved set of diagnostic criteria [@R72] that uses current understanding of the natural history and genetic characteristics of NF2 to increase sensitivity while maintaining very high specificity ([Table II](#T2){ref-type="table"}): these criteria currently permit early diagnosis in a greater proportion of patients with NF2 than previous sets of diagnostic criteria [@R72].

###### 

The Baser criteria for diagnosis of NF2 \[2011\] [@R71] [@R72].

  Feature                                                                If present at or \< age 30 years   If present \> age 30 years
  ---------------------------------------------------------------------- ---------------------------------- -------------------------------------
  First-degree relative with NF2 diagnosed by these criteria             2                                  2
  Unilateral vestibular schwannoma                                       2                                  1[^a^](#T2FN2){ref-type="table-fn"}
  Second vestibular schwannoma                                           4                                  3[^a^](#T2FN2){ref-type="table-fn"}
  One meningioma                                                         2                                  1
  Second meningioma (no additional points for \> than 2 meningiomas)     2                                  1
  Cutaneous schwannomas (one or more)                                    2                                  1
  Cranial nerve tumour (excluding vestibular schwannoma) (one or more)   2                                  1
  Mononeuropathy                                                         2                                  1
  Cataract (one or more)                                                 2                                  0

The patient is given points as shown in the table.

Points are not given for unilateral or second vestibular schwannoma if age at diagnosis is more than 70 yr.

• A diagnosis of definite NF2 is established if the total number of points is 6 or more.

• A diagnosis of definite NF2 is established if a constitutional pathogenic NF2 mutation is found on mutation testing.

• If no constitutional pathogenic NF2 mutation is found on mutation testing:

\- A diagnosis of mosaic NF2 is established if mosaicism for a pathogenic NF2 mutation is found in the blood or no detectable pathogenic NF2 mutation is found in the blood but the same pathogenic NF2 mutation is found in two separate NF2-associated tumours.- Otherwise, a temporary diagnosis of possible NF2 is made, pending further clarification. Clarification may occur if the patient is established to have a different condition (e.g., schwannomatosis or multiple meningiomas) by standard diagnostic criteria or if evolution of the patient\'s disease over time permits establishing a diagnosis of definite NF2 or mosaic NF2 according to the criteria given above.

Initial evaluation {#S6}
==================

Initial evaluation of children who have or are at risk for NF2 should include testing to confirm a diagnosis and to identify potential problems [@R19]^-^[@R33].

A medical history should include questions about focal neurologic symptoms, skin tumours and/or cutaneous spots, seizures, headache, and visual symptoms as well as auditory and vestibular function. A family history should explore unexplained neurological and audiology symptoms in all first-degree relatives.

MRI scan of the brain should include gadolinium and include axial and coronal thin cuts (1-3 mm) through the brainstem to identify VSs [@R23] [@R28] [@R34]. MRI scan of the cervical spine should be performed given the predilection of ependymomas for this site and of meningiomas and/or schwannomas for the paravertebral regions [@R28] [@R34]. Some clinicians recommend imaging of the thoracic and lumbar spine whereas others reserve these exams for patients with neurologic symptoms referable to these locations [@R02]^-^[@R04] [@R19] [@R28].

Ophthalmologic examination serves to identify characteristic lesions such as lens opacities, retinal hamartomas, or epiretinal membranes [@R19] [@R23] [@R26] [@R28].

A complete neurological examination serves as a baseline for future comparison and may assist in the selection of sites within the nervous system that require further imaging studies.

Audiology (including pure tone threshold and word recognition) and brainstem auditory evoked responses (BAER) document eighth cranial nerve dysfunction related to VSs and set a baseline for future comparisons. Abnormalities of pure tone thresholds are present in 90% of patients between 10 and 72 years with NF2. Word recognition serves as a measure of functional hearing. BAERs are a more sensitive measure of auditory function and is abnormal in 100% of patients with symptomatic VSs. In cases where the diagnosis is uncertain, biopsy of any skin lesion and review of any pathologic material may be helpful.

Follow-up {#S7}
=========

After initial diagnosis, children should be seen relatively frequently (every 3-6 months) until the growth rate and biologic behaviour of tumours is determined (this holds especially true in congenital NF2). Consultation with an experienced surgeon after initial diagnosis is often helpful for pre-symptomatic patients (i.e., those with adequate hearing) to discuss the feasibility of hearing-sparing surgery (see below). Most patients without acute problems can be followed on a 6-month to an annual basis. Evaluation at these visits should include complete neurological examination, MRI scan of the brain and spinal cord with thin cuts through the brainstem, MRI scans of symptomatic lesions outside the brain if present, audiology, and BAER. Ophthalmologic evaluation should be performed in selected patients with visual impairment or facial weakness. Yearly audiology serves to document changes in pure tone threshold and word recognition. This information can be helpful in planning early surgical intervention for VSs and in counselling patients about possible deafness. Changes in BAERs may precede hearing loss. The frequency with which routine spinal imaging is obtained varies among clinics, but is clearly indicated in patients with new or progressive symptoms referable to the spinal cord. We prefer to obtain it at every MRI follow-up, unless there is no evidence of spinal tumours on first scan. In adulthood less frequent screening on a 3-5 yearly basis is warranted.

Classical management of childhood NF2 {#S8}
=====================================

The approach to management of NF2-asociated tumours has been always different from that of their sporadic counterparts. Because children (but also adults) with NF2 develop multiple cranial, spinal and peripheral nerve tumours, surgical removal of every lesion is not possible or advisable. Instead, the primary goal has been (and still is) to preserve function and to minimize quality of life.

Currently, despite frequent functional impairment, surgical removal remains the standard therapy for VSs (and for non-VSs nervous system tumours): indeed, patients undergoing surgery for VSs often experience iatrogenic hearing loss in the treated ear requiring rehabilitation through the use of a cochlear implant or an auditory brainstem implant (ABI). As an alternative or in addition to tumour removal, stereotactic irradiation and/or chemotherapy can be used to delay tumour progression, but it is thought to increase the risk for secondary malignancies in these patients. Moreover, radiation therapy frequently accelerates loss of hearing. Complete surgical resection is curative, but the timing for tumour removal is controversial, with a complex risk-benefit ratio, between risks of surgery and tumour\'s natural history.

Until the last decade, the above strategies were the sole therapeutic options for NF2-related vestibular schwannomas, and more in general for NF2-associated tumours: more recent biologically targeted therapies (see below) employing molecules driven from the increased knowledge of the molecular pathways involved in the pathogenesis of NF2 have been successfully employed in adult and paediatric patients with NF2. As these newer therapeutic options have been employed only very recently and in a limited number of NF2 children and are still under study here below, we will review the classical management options still employed worldwide.

Surgical strategies. {#S8a}
--------------------

The tumour load in childhood NF2 series [@R06] [@R14] [@R15] [@R20] is usually extensive and involves the skin, brain and spine.

Few NF2 children undergo resection of dermal tumours because of cosmetic burden [@R23] [@R28] [@R34]; this is in line with the patterns of growth of peripheral schwannomas, which rarely are disfiguring at this young ages [@R06] [@R15] [@R20]. Interestingly, resection of typical NF2-plaques is being asked for diagnostic clarification as in the paediatric population VSs are not apparent until older ages [@R28].

Surgery is clearly indicated for NF2 children with significant brainstem or spinal cord compression or with obstructive hydrocephalus. In patients with little or no neurological dysfunction related to their tumours, watchful waiting may allow children to retain neurological function for many years. For this reason, timing of intervention is often a difficult decision for patients and physicians.

A great number of NF2 children imaged have usually one or more extradural spinal masses compatible with schwannomas or meningiomas. Despite this extensive load of spinal nerve sheath tumours only rarely at these young ages these tumours indent the cord itself and require surgical removal because of progressive spinal cord impairment. Resection is usually successful in the majority of NF2 children with spinal tumours (usually ependymomas) without need of repeated neurosurgical intervention or regrowth [@R23] [@R28]^-^[@R30]. Conversely, pontine (and bulbar) tumours (usually, ependymomas and astrocytomas) most often need repeated partial resection with severe sequelae. According to our experience, the tumour burden in this location is high and changes the course of disease. As a general rule, indications for resection include rapid tumour growth and worsening neurologic symptoms. In contrast to what occur with brainstem tumours in NF1 (which are low grade astrocytomas, are often asymptomatic and have an indolent course with later tumour regression) these tumours\' location in NF2 is associated with higher-grade histology, relentlessly progressive course and often a fatal outcome. However, the mere presence of an asymptomatic ependymoma should prompt a watch and wait policy as many remain indolent.

The decision to operate early on vestibular schwannomas or wait until symptoms or complete deafness ensue is difficult. Recent consensus proposed surgical resection of the largest tumours (\> 3 cm in diameter) permitting facial nerve preservation and brainstem protection [@R23] [@R28]. There is no consensus for the management of VS less than 3 cm in diameter. Unresectable tumours and hearing impairment following surgery justify the introduction of new effective and safe therapies (see below). Surgical extirpation of VSs is usually accomplished using middle cranial fossa, posterior sub-occipital, and trans-labyrinthine approaches. The goal of pre-symptomatic surgery is retention of hearing with a minimum of post-operative complications such as facial weakness or dysphagia. In patients with a documented change in hearing, bony decompression of the internal auditory canal through a middle cranial fossa can stabilize hearing for a period of time. Pre-operative tumour size as an indicator of outcome in VSs surgery is still debated. A sub-occipital approach for small tumours can result in hearing preservation although precise numbers using this technique have not been published. Alternatively, a trans-labyrinthine approach with placement of an auditory brainstem implant (ABI) can provide auditory sensations in some patients. Children opting for this approach should be counselled that about 10% of patients do not receive auditory sensations, that ABI\'s do not provide normal sound quality, that processor optimisation requires regular follow-up, and that maximal benefit is often not achieved for many years [@R110]. For most patients with ABI\'s, the primary benefit occurs when the implant is used in conjunction with lip reading. At the present time, little information is available about the efficacy of hearing sparing surgery in paediatric NF2 patients but outcomes appear to be inferior to that for adults.[@R111] A further option is cochlear nerve preserving surgery when the tumour is small via the translabarynthine approach and insertion of a cochlear implant that produces far superior results to ABI [@R112].

The decision to proceed with hearing-sparing surgery must be individualised for each patient. Options include observation without surgical intervention and hearingsparing surgery; stereotactic radiation has not yielded comparable results for preservation of hearing (see below). For those with tumours that are multilobulated or greater than 1.5 cm in greatest dimension, the risk of peri-operative complications (including hearing loss and cranial nerve dysfunction) likely outweighs the potential benefits. In these patients, tumour resection should be deferred until another indication for surgery such as increased intracranial pressure, impending hydrocephalus, or new neurologic symptoms develops.

Indications for surgical resection of other (non-VSs) cranial nerve schwannomas are less well defined. In general, schwannomas of other cranial nerves are slow growing and produce few symptoms. Surgical resection in these patients should be reserved for those with unacceptable neurologic symptoms or rapid tumour growth.

Radiation therapy. {#S8b}
------------------

Radiation is often used as adjuvant therapy for treatment of sporadic brain tumours. Treatment outcomes for (paediatric and adult) patients with NF2-related VSs are worse than for patients with sporadic tumours. In early studies of stereotactic radiosurgery, 18-20 Gy were delivered to tumours. Local control was achieved in 90% of patients but no serviceable hearing was preserved in patients with serviceable hearing pre-operatively. For this reason, the dose of radiation to the tumour margin was reduced to 12-16 Gy. Using modern regimens, treatment with stereotactic radiosurgery results in tumour control in 98% of patients with NF2 with preservation of useful hearing in 40-67%. Decreased facial and trigeminal function occurs in 5-16% and 10% of patients, respectively. The risk of deafness in patients with serviceable hearing pre-operatively is about 20%. More recently, fractionated stereotactic radiotherapy has been advocated to minimise the risk of hearing loss. The actuarial 5-year local control rate using this technique is 93% and the hearing-preservation rate is 64%. The use of radiation therapy for benign tumours in NF2 children must nonetheless be used with caution because of the greater risk of future tumour induction and malignant transformation [@R82].

The role of adjuvant radiation in other tumours such as meningiomas and ependymomas is not established, but the majority of these tumours demonstrate benign histology and can be controlled surgically. No case series have been published on treatment of NF2-related meningiomas. In general, treatment of sporadic tumours with stereotactic radiosurgery results in local control in 90- 95% of cases. Peritumoural cerebral oedema develops in up to 25% of patients, but symptoms referable to cerebral oedema develop in less than 10% of patients.

Most clinicians prefer surgical extirpation of tumours when possible and reserve radiation treatment for tumours that are not surgically accessible. This practice is based on the experience that radiation therapy makes subsequent resection of VSs and function of ABI\'s more difficult. In addition, there are anecdotal reports of malignant transformation of NF2-associated schwannomas after radiation treatment and indirect evidence of increased numbers of malignancy in NF2 patients who have received radiation.

Chemotherapy. {#S8c}
-------------

At the present time, there is no effective chemotherapy for treatment of NF2-related tumours. Sporadic meningiomas represent the best-studied tumour at the present time. Typically, patients with refractory or nonsurgical tumours have been included in chemotherapy trials. Although some initial reports suggested efficacy of hydroxyurea in treating meningiomas, more recent reports do not support this view. Furthermore, there seems to be little role for use of tamoxifen or temozolomide for recurrent tumours. No trials of chemotherapy for treatment of vestibular schwannomas or ependymomas have been reported. Gene therapy remains a potential option for the future as injection of oncolytic recombinant herpes virus into schwannomas in mice results in significant tumour shrinkage.

NF2 patients who are managed at multidisciplinary specialty treatment centres have a significantly lower risk of mortality than those who are treated at non-specialty centres with higher rates of favourable outcome in VSs surgery and lower rates of serious complications with increasing surgical experience [@R02] [@R07].

Genetic counselling. {#S8d}
--------------------

Individuals at risk for NF2 need genetic counselling and pre-symptomatic testing. Clinically, a normal MR image at 16 or 18 years reduces the chances of having inherited NF2. A normal MRI at 30 years makes inheritance very unlikely, except in late-onset families, and may justify cessation of formal screening [@R113]. Notably, most of our NF2 cases were sporadic and the earlier the onset of NF2 the lower the risk for siblings and parents.

As clinical and radiological screening cannot reassure atrisk individuals that they have not inherited the condition until 30 years of age, molecular genetic testing for NF2 has had a major impact on clinical practice[@R02] [@R05]. Constitutional mutation testing for NF2 is now available worldwide and mutations are found in about half the sporadic individuals tested but over 90% of families with vertical transmission [@R45]. Identified mutations can be used for a presymptomatic testing and the latter is warranted even in children.

Biologically targeted pharmacological strategies in childhood NF2 {#S9}
=================================================================

Recently, following the studies on merlin pathway(s), different pharmacological strategies have been developed, in order to obtain tumour volumetric shrinkage and/or arrest of progression of tumours including a reduction in time to progression [@R114]. Given the complexity of the Merlin\'s pathway(s), different targets have been proposed [@R115]^-^[@R121].

Antagonists of the ErbB family. {#S9a}
-------------------------------

Lapatinib, an antagonists of the Her1-2members of the ErbB family of tyrosine kinase receptors,was clinically tested in NF2-patients, with volumetric regression of VSs and improvement of hearing, in 4 of 17 patients treated [@R122]; however, patients treated with another inhibitor of ErbB tyrosine kinase receptors, Erlotinib, did not experience tumour regression, even if in 27% of the cases there was a stabilisation of the disease [@R123].

Inhibitors of the mTOR pathway. {#S9b}
-------------------------------

The attempt to use mTOR pathway inhibition (i.e., Everolimus) did not yield appreciable results, with no patients (out of 9 enrolled) showing a volumetric response of the schwannomas, nor clear evidence of a stabilization of the disease) [@R124].

Inhibitors of IGF1 receptor/PDGF/Akt/MEK. {#S9c}
-----------------------------------------

In vitro studies on the employment of different potential drugs have shown appreciable results, in particular with picropodophyllin, an anti-IGF1 receptor [@R125], OSU-03012, an Akt inhibitor [@R126], and nilotinib, a C-kit cascade inhibitor [@R127].

Imatinib, a PDGF inhibitor [@R128], has also been employed in a NF2 patient 129. Even if preliminary results were appreciable, the treatment was suspended after only 4 months for severe adverse reactions, including headache, vomiting, abdominal pain and increased unsteadiness. Sorafenib, which acts by inhibiting C-kit, PDGF and MEK1-2 system, was employed in a single patient and afterward suspended because of the appearance of a rash [@R130].

Anti-VEGF antibodies. {#S9d}
---------------------

Bevacizumab, a monoclonal antibody directed against anti-vascular endothelial growth factor (VEGF)has shown the most promising results in terms of tumour volume shrinkage, stabilisation of the disease and hearing improvement, since its first employment by Plotkin et al, at the dose of 5 mg/kg/biweekly ([Fig. 13](#F13){ref-type="fig"}) [@R131]. Even if associated with different side effects (including haemorrhage, delayed wound healing, proteinuria and hypertension) [@R132] it is by and large extremely well tolerated in NF2 patients [@R133]. Bevacizumab has demonstrated its efficacy in the treatment of VSs [@R129] [@R131] [@R134], with a stable or improved hearing in 90% of patients after 1 year and 61% after 3 years [@R135]; a stable or decreased tumour volume was observed in 88% of patients after 1 year of treatment and in 54% at 3 years. The same usefulness was not demonstrated in the meningiomas of the same cohort of NF2 patients [@R135] [@R136]: a volumetric response was observed in 29% and the median duration of the response was 3.7 months and a median time to progression of 15 months.

![VEGF/VEGFR signalling pathway in normal vs. NF2 Schwann cells \[Avastin\]: in normal Schwann cells VEGF (vascular endothelial growth factor), SEMA3A (semaphorin 3 A) and SEMAF (semaphorin F) molecules and VEGFR (VEGF receptors), NRP (neuropilin) and Plexin receptors are normally expressed; in NF2 Schwann cells VEGF are normally expressed vs. lower expressed VEGFR; in addition to that, in NF2 Schwann cells NRP and Plexin receptors are normally expressed vs. lower expressed SEMA3A and SEMAF molecules (see boxes). VEGF typically binds to VEGFR2 \[Panel 1\] inducing endothelial proliferation, migration and permeability; VEGF can also compete with SEMA3A to bind to Neuropilin (NRP) receptors directly or can form a bridge between VEGFR2 and NRP potentiating its signalling via VEGFR2 \[Panel 2\]; SEMA3A and SEMAF bind NRP1 and NRP2, respectively, to induce endothelial cell regression and diminished permeability \[Panel 3\]. Thus, Avastin \[an anti-VEGF antibody\], when administered in NF2 patients acts not only via VEGFR inhibition (as VEGFR are lower expressed in NF2 Schwann cells) but also because it displaces VEGF from binding to NRP and Plexin receptor, thus allowing SEMA3A and SEMAF to bind to these receptors inducing endothelial cell regression and diminished permeability \[see Panel 3 (from Ruggieri et al., 2015 [@R35] and Ruggieri et al., 2015 [@R36], adapted and modified).](0392-100X-36-345-g013){#F13}

Among the 10 patients affected by non-malignant brain tumours and treated with anti-VEGF therapy enrolled by Hawasli et al. [@R136], six were affected by NF2: 5were treated with bevacizumab, and one with pazopanib, a pleiotropic tyrosine kinase receptor inhibitor, which inhibits also the angiogenesis. All the six NF2 patients showed benefits from anti-VEGF, while among the non-NF2 patients, two (affected by recurrent meningiomas) continued to present tumour growth after VEGF therapy.

Subbiah et al. [@R129] demonstrated the utility of a combined treatment with bevacizumab and temsirolimus, an mTOR inhibitor, in two patients: one of them had a 33% volumetric response in size, while the other presented a stable disease.

A radiological response was observed in 7 of 18 tumours (39%) of the 12 patients enrolled by Alanin et al. [@R137], with a continued response (for more than 2 months) in 6/18 (33%). Three patients (25%) showed an objective hearing improvement and five (41.7%) reported subjective benefit in neurological symptoms, including improved hearing.

Anti-VEGF in the paediatric age ([Table III](#T3){ref-type="table"}) ([Fig. 13](#F13){ref-type="fig"}). {#S9e}
-------------------------------------------------------------------------------------------------------

###### 

NF2 patients treated with bevacizumab in the literature (from Ruggieri et al., 2015 [@R35] and Ruggieri et al., 2015 [@R36], adapted and modified).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                 Year      Total\   Average\      Age\      Sex     Median\          Hearing\         Radiologic Response          Side effects
                                   no.      age\          range\            duration of\     Response                                      
                                            \[Current\]   (years)           Treatment                                                      
  ---------------------- --------- -------- ------------- --------- ------- ---------------- ---------------- ---------------------------- ------------------------------
  Plotkin et al          2009 &\   31       26            12-73     14 M\   14 months        90% had\         17/31 (55%) reduction in\    50% menorrhagia\
                         2012                                       17 F                     stable or\       size of VS; 10/31 stable\    and Irregular\
                                                                                             improved\        disease (32%). \[87% of\     menstruation; 35%\
                                                                                             hearing after\   patients had stable or\      proteinuria and\
                                                                                             1 year of\       decreased tumour size\       hypertension; 26%\
                                                                                             treatment and\   after 1 year of treatment\   epistaxis; 23% fatigue\
                                                                                             61% at 3 years   and 54% at 3 years\]         and hyponatremia

  Mautner et al          2010      2        31            23-39     2 M     1 year           1/2\             2/2 volumetric\              Patient 1: slightly fatigue\
                                                                                             improvement      reduction                    and epistaxis; Patient 2\
                                                                                                                                           hypertension

  Eminowicz et al        2012      2        34            31-37     1 M\    Case 1 18\       2/2\             2/2 volumetric\              NR
                                                                    1 F     weeks; Case 2\   improvement      reduction                    
                                                                            \> 16 weeks                                                    

  Riina et al\           2012      3        39.7          31-56     2 M\    1 day            NA               Patient 1: Reduction\        None
  \[Intra-arterial\                                                 1 F                                       11 and 19% of VSs;\          
  infusion\]                                                                                                  Patient 2: stable\           
                                                                                                              disease; Patient 3:\         
                                                                                                              stable disease               

  Subbiah et al\         2012      4        30            16-41     2 M\    (4-10+ monts)    3/4 stable\      3/4 stable disease; 1/4\     2/4 proteinuria and\
  \[Total 6 patients;\                                              2 F                      disease; 1/4\    33% tumour shrinkage         hyperlipidemia
  4 treated wit\                                                                             improvement                                   
  BEV\]                                                                                                                                    

  Hawasli et\            2013      5        22,8          14-38     NR      11 months        2/5 stable\      4/5 stable; 1/5\             2/5 hypertentsion; 1/5\
  al \[Total 10\                                                                             disease; 3/5\    volumetric reduction         epistaxis; 1/5 weight\
  patients; 5\                                                                               improvement                                   loss; 1/5 abdominal pain\
  affected by NF2\                                                                                                                         and diarrhea; 1/5 chest\
  and treated with\                                                                                                                        pain
  BEV\]                                                                                                                                    

  Nunes et al\           2013      15       29.5          16-63     7 M\    18 months        NA               29% (14/48\                  4 grade 3 adverse\
  \[Meningiomas;\                                                   8 F                                       meningiomas):\               events (hypertension,\
  Same patients\                                                                                              volumetric radiographic\     elevated liver enzymes,\
  of Plotkin 2012\]                                                                                           response; median time\       menorrhagia, irregular\
                                                                                                              to progression was\          menses) and 2 grade 4\
                                                                                                              15 months. Median\           events (delayed wound\
                                                                                                              duration of response\        healing)
                                                                                                              was 3.7 months               

  Alanin et al           2014      12       34            23-78     5 M\    22 months\       5/12\            6/12 radiologic\             92% fatigue; 71%\
                                                                    7 F     (range 7-34)     subjective\      response                     oligomenorrhea; 67%\
                                                                                             benefit; 3/12\                                proteinuria; 33%\
                                                                                             objective\                                    hypertension; 17%\
                                                                                             benefit                                       epistaxis; one patient\
                                                                                                                                           presented cerebral\
                                                                                                                                           haemorrhage (fatal\
                                                                                                                                           event)

  Farschtschi\           2015      3        28.3          22-38     2 M\    66-76 months     3/3 hearing\     3/3 radiologic response      Hypertension 3/3;\
  et al \[reduced\                                                  1 F                      improvement                                   proteinuria 2/3; The\
  dosage; 5 to 2.5\                                                                                                                        side effects ceased after\
  mg\]                                                                                                                                     treatment reduction to\
                                                                                                                                           2.5 mg/g

  Hochart et al          2015      7        15            11.4-\    3 M\    11.3 months\     3/7 stable;\     3/7 shrinkage; 2/7\          1/7 severe hypertension\
                                                          18.8      4 F     (range 3.2-\     3/7 Non\         Reduction of growth\         and proteinuria; 1/7\
                                                                            55.6)            elegible; 1/7\   rate; 1/7 stable disease     osteomyelitis; 1/7\
                                                                                             improvement                                   epistaxis; 1/7 intermensual\
                                                                                                                                           bleeding; 1/7\
                                                                                                                                           malaise

  Morris KA et al        2016      61       25            10-57     36\     23 months\       Hearing\         Partial volumetric\          Hypertension in 30%\
                                                                    M 25\   (range 3-53)     stabilisation\   tumour response (all\        and proteinuria in 16%.\
                                                                    F                        or\              tumours) was in 39%\         12/61 treatment breaks.
                                                                                             improvement\     and stabilisation in 51%     
                                                                                             in 86%                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend: BEV = Bevacizumab; NR = Not reported; NA = Not available; VS = Vestibular schwannoma

Among the seven children and teenagers affected by NF2 (median age 15 years) treated by Hochartet al. [@R138], one showed a tumour regression of more than 20%, two a tumour shrinkage between 5 and 19% and the other four showed a decreased tumour growth. A hearing benefit was showed in 1 out 4 patients eligible for audiometric evaluation, while the others presented a stable disease [@R138]. Severe adverse (hypertension and osteitis) events were registered in two patients, who had to discontinue treatment; another patient needed a reduction of the doses after recurrent episodes of epistaxis, while another experienced a grade 2 inter-menstrual bleeding. Six children with NF2 with 8 evaluable VS had significantly poorer responses to bevacizumab than 51 adults in a large multi-institution study [@R133]. Other smaller groups of NF2-related tumours have been treated with bevacizumab. These studies have demonstrated that a reduced dose bevacizumab treatment to 2.5 mg bi- or tri-weekly, also if prolonged for 66-76 months, could still provide a clinically stable, radiographic and audiology sustained response [@R139], that tumour shrinkage can be more than 40% [@R140], and that bevacizumab can also be effective in patients previously unsuccessfully treated with gamma knife radiotherapy [@R141]. Moreover, a super-selective intra-arterial cerebral infusion of bevacizumab was reported in 3 patients has showed a likely efficacy, with one patient presenting a decreased tumour volume and two showing a stable disease [@R142].

Mortality in NF2 and in NF2 children {#S10}
====================================

Overall, patients with NF2 have diminished lifespan compared to non-affected family members [@R106] [@R107] [@R143] with overall 5-, 10-, and 20-years survival rates after diagnosis of 85%, 67% and 38%, respectively [@R137]. Early age at diagnosis and the presence of intracranial meningiomas are usually associated with increased mortality, and having a mosaic, rather than non-mosaic, NF2 mutation is associated with reduced mortality [@R106]. The most frequent causes of death include tumour burden, peri-operative complications, and malignancy from NF2-related tumour [@R28] [@R107] [@R143]. A decreased risk of mortality is associated with treatment at a specialty medical centre and with splice-site or missense mutations vs. truncating mutations \[patients with splicesite mutations in exons 6-15 have lower mortality than patients with splice-site mutations in exons 1-5\]. Notably, the overall mortality of children and adults with NF2 diagnosed in more recent decades is lower than that of patients diagnosed earlier [@R28] [@R106].
